• Latest Posts

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

German Biotech Clears Phase I with New Gene Therapy for Glaucoma

Interview 11 May 2017

Video: Meet the CEO developing Gene Therapy without Viral Vectors

France Approves Trials for the First Eye Gene Therapy Free of Viral DNA

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease


A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

French Startup raised €4M for Gene Therapy to fix specific Types of Blindness

Novel Bionic Vision device gains approval for clinical trials in Renowned UK Hospital

Biotech of the Week: ThromboGenics & Therapies against Eye Disease

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field